Philippines Radiotherapy Market- Insights
Radiotherapy, also known as radiation therapy, uses ionizing radiations that deliver targeted beams of radiation to kill and destroy cancer cells. The advanced technology used in radiotherapy works by bombarding cancerous cells with radiation to kill them, while minimizing damage to the healthy cells around them. Radiotherapy is the most potent treatment for cancer and when integrated with advanced technologies such as image guided therapy, which leads to enhanced control over tumor and toxicity.
Initiatives by various organizations to increase accessibility to radiotherapy is expected to support the market growth
Increasing initiatives by various government organizations to increase access to radiotherapy among patients suffering from cancer in Philippines is expected to create lucrative environment for the Philippines radiotherapy market growth.
For instance, due to high prevalence of cancer in Philippines, the Department of Health (DOH), Philippines, in 2016, decided to strategically establish cancer centers in hospitals to make quality radiation therapy services more accessible to cancer patients, especially those outside Metro Manila.
According to DOH, following hospitals had linear accelerators and other devices installed in the facility; Southern Philippines Medical Center, Cagayan Valley Medical Center, Baguio General Hospital and Medical Center, Bicol Medical Center, Zamboanga City Medical Center, Lung Center of the Philippines, and Vicente Sotto Memorial Medical Center.
Philippines radiotherapy market size was valued at US$ 17.6 Mn in 2018 and is expected to witness a CAGR of 5.8% during the forecast period (2018 – 2026).
Figure 1. Philippines Radiotherapy Market Value (US$ Mn) Analysis and Forecast & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2018)
High prevalence of cancer is expected to increase demand for its treatment and support the market growth
High prevalence of cancer in Philippines is expected to significantly increase the demand for its treatment procedures including radiotherapy and significantly support the Philippines radiotherapy market growth. For instance, according to the data published by Philippines Statistics Authority, in February 2018, neoplasms (also called as cancer) was found to be second leading cause of death after ischemic heart disease in Philippines and accounted for 10.4% of total death cases or around 60,470 death in 2016.
According to the Philippines Cancer Society in 2017, around 109,280 new cases of cancer were diagnosed among which around 48,138 were males and 61,142 were females.
High price and presence of alternative to radiotherapy is expected to be major factor negatively affecting the Philippines radiotherapy market growth
High price of radiotherapy devices such as CyberKnife and Gamma knife is expected to be one reason limiting its adoption, as setup of such devices needs high investment, which is not easily affordable by small hospitals in Philippines. Hence, high price of novel radiotherapy devices is expected to be a major factor limiting its adoption and restraining the market growth in Philippines.
For instance, according to the data published by First Dayton Cancer Care, CyberKnife is more expensive than ordinary linear accelerator devices. Investment cost for setting up such device is around US$ 5 million.
Furthermore, presence of alternative methods such as chemotherapy is expected to affect the adoption of radiotherapy and restrain market growth
Figure 2. Philippines Radiotherapy Market Share (%), By Product Type, 2018-2026
Source: Coherent Market Insights Analysis (2018)
The prevalence of cancer is very high in Philippines and it was found to be second leading cause of death, according to the Philippines Statistics Authority estimates, in 2016.
Furthermore, access to radiotherapy is less in Philippines due to less adoption of devices such as Gamma Knife and CyberKnife.
There is a wide gap between the patient and radiotherapy treatment providers. Hence, key players in the market have opportunity to fill this gap by installing their devices in the region and fulfill these unmet needs.
In 2017, Philippines implemented new customs clearance procedure for radiation devices.
According to the new guidelines, radiation-emitting medical devices are subjected to a new customs clearance release procedure administered by the Philippines FDA.
For shipment of each radiation-emitting devices in Philippines, importers must obtain Clearance for Customs Release (CFCR) certificate issued by the FDA’s Center for Device Regulation, Radiation Health, and Research (CDRRHR). Applications are processed within 3 working days for a fee of US$ 6 (Philippines Peso 300) per device.
One of the required elements of the CFCR application is a certificate of product registration issued by the national authority in the country of origin. This document must be authenticated by the Philippines embassy in the country of origin.
Key players operating in the Philippines radiotherapy market include Elekta AB, Accuray Incorporated, Varian Medical Systems, Inc., RaySearch Laboratories AB, Mevion Medical Systems, Inc., Isoray Inc., Nordion Inc., Becton, Dickinson and Company, Ion Beam Applications SA, and Hitachi, Ltd.
Radiation therapy or radiotherapy is a cancer treatment therapy, which uses high doses of radiations to kill cancer cells and shrink tumors. Several types of radiotherapies such as external beam radiation therapy, internal beam radiation therapy/ brachytherapy, and systemic radiation therapy are available to combat various types of cancers prevalent, globally. External beam radiation therapy is used to treat various types of cancers, including brain tumors, bladder cancer, and bone cancers. Brachytherapy is often used to treat cancers of the head and neck, breast, cervix, prostate, and eye, while systemic radiation therapy is often used to treat certain types of thyroid cancers using radioactive iodine.
Installment of novel technologically advanced radiotherapy equipment in Philippines for the treatment of various types cancer is expected to drive the Philippines radiotherapy market growth over the forecast period.
For instance, in 2015, the Philippine Gamma Knife Center at Manila’s Cardinal Santos Medical Center acquired Elekta’s Leksell Gamma Knife Perfexion stereotactic radiosurgery system, an advanced radiosurgery device with high accuracy, which is used for the treatment of brain and neck tumors.
High prevalence of cancers in Philippines is expected to be another factor increasing demand for radiotherapy for its treatment and significantly support Philippines radiotherapy market growth in near future.
As per the Philippine Cancer Society estimates in 2015, around 2,104 people suffered from leukemia, which accounts for 3% of the total cancer cases and around 1,160 people suffered from non-Hodgkin Lymphoma, which accounts for around 2% of all cancer cases
Furthermore, rising geriatric population in Philippines is expected to increase the chances of prostate cancer in males, which in turn is expected to increase demand for novel treatments such as radiotherapy for its treatment. For instance, according to the HelpAge, there were around 5,905,000 old people in Philippines in 2012, which is expected to reach around 23,633,000 by 2050.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 30 market data tables and 31 figures on “Philippines Radiotherapy Market -forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.